If clinical trials are successful and the FDA approves the drug, it could be available across the United States later in 2021
THURSDAY, April 29, 2021 (HealthDay News) — A pill to treat COVID-19 is being developed by Pfizer and could be available by the end of the year, company CEO Albert Bourla says.
In March, Pfizer launched an early-stage clinical trial of a new antiviral drug for the coronavirus that causes COVID-19, CBS News reported. The drug reduces the production of enzymes the virus needs to multiply in human cells.
If clinical trials are successful and the U.S. Food and Drug Administration approves the drug, it could be available across the United States later in 2021, Bourla told CNBC on Tuesday, CBS News reported.
Last month, Mikael Dolsten, M.D., chief scientific officer and president, worldwide research, development, and medical of Pfizer, said it is possible that the new drug could be prescribed “at the first sign of infection, without requiring that patients are hospitalized or in critical care.”
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL 
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors .jpg)
Recommendations Updated for Management of Anemia in CKD 
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus 
Therapies Compared for Newly Diagnosed Multiple Sclerosis 
Initial Rx Length Tied to Long-Term Use of Z-Drugs 
Distinct Characteristics ID"d for Patients With Rheumatoid Conditions, Opioid Use Disorder 
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML 
.jpg)